"We can pass 10 executive orders. We can put $500 million for drug development. And if we don't have people who are willing to hold that space... we're not going to get anywhere." - Ismail Lourido Ali, MAP Co-CEO
On April 18th, just days before 420, Bicycle Day and MAPS’ own 40th anniversary, Donald Trump signed an executive order on psychedelics. But what does it mean? Especially for psychedelic practitioners themselves.

Today on the Psychedelic Therapy Podcast I sit down with MAPS Co-Executive Director Ismail Lourido Ali to learn what it actually means for the people doing the work. Together we unpack the executive order from the ground up: what it legally can and can't do, why ibogaine has suddenly kicked down the door while MDMA and psilocybin wait in line, and the strange political alchemy that made this happen. We cover the key distinctions between decriminalization, medicalization, and legalization; MAPS' evolving role as a multicultural bridge-builder at this pivot point; the sovereignty of Gabon and the very real risks of biopiracy in ibogaine's commercialization; and the danger of silver-bullet thinking. The conversation ends with the practitioners themselves, and the irreplaceable human work of preparation, presence, and integration that no executive order can replicate.

Ismail Lourido Ali, JD is the Co-Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies) alongside co-director Betty Aldworth. A philosopher by training and a lawyer by vocation, he previously served as MAPS Director of Policy, worked in criminal justice reform at the ACLU of Northern California, and co-founded the Psychedelic Bar Association. He has been active in psychedelic drug policy reform for over a decade.

Timestamps: 

• (01:00) Ismail's first six months as MAPS Co-CEO 
• (07:00) Decrim, medicalization, legalization 
• (12:00) What Trump's executive order actually does (and doesn't do) 
• (19:00) Why ibogaine? Origins, the opioid crisis, and the perfect storm 
• (30:00) The political alchemy behind the signing 
• (34:00) Where MAPS fits in this pivotal moment 
• (46:00) The Nagoya Protocol, Gabon's sovereignty, and the risk of biopiracy 
• (56:00) Silver bullets vs. real healing

Links:

• Ismail L. Ali, J.D., Co-Executive Director — MAPS
• Ismail Lourido Ali (@sage_izzy)
• MAPS Board Names Aldworth and Ali as Co-Executive Directors
• A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter